Black checkmark with a sparkle and a curved line underneath on a white background.
Company

CUMBERLAND PHARMACEUTICALS INC

Ticker
CPIX
Sector
Industry
Report date
November 14, 2026
Valye AI Score

100

Very high visibility
Recent developments
Recent developments summary

Recent developments highlight Cumberland Pharmaceuticals' clinical progress, regulatory filings, and financial updates.

Recent developments:
  • Cumberland Pharmaceuticals held its Q3 earnings call providing operational and financial updates. [N1]
  • The company began rolling submission of an FDA New Drug Application for Dyscorban in Duchenne cardiomyopathy, a rare genetic disease. [N2]
  • Top-line results from the Phase 2a ASSIST-SSc trial for ifetroban in Systemic Sclerosis were announced. [N3]
  • Q2 earnings call highlighted ongoing commercial momentum and financial performance. [N4]
  • Cumberland was noted among top biotech gainers ahead of Q2 results, reflecting market interest. [N5]
  • Discussions on possible generic drug tariffs and impacts on microcap pharmaceutical companies included Cumberland. [N6]
  • Research indicated ifetroban's potential to limit metastasis, expanding its therapeutic interest. [N7]
  • The company expanded its global reach with the launch of Vibativ in China. [N8]
Overview

Cumberland Pharmaceuticals Inc. operates as a specialty pharmaceutical company dedicated to acquiring, developing, and commercializing branded prescription pharmaceuticals. Its primary markets are hospital acute care, gastroenterology, and oncology, served through targeted sales forces in the U.S. and international partnerships. The company markets several FDA-approved products addressing conditions such as acetaminophen poisoning, pain and fever, constipation, chemotherapy-induced nausea and vomiting, hyponatremia, serious bacterial infections, and H. pylori infection. Cumberland also pursues clinical development of ifetroban for rare diseases including Duchenne muscular dystrophy and systemic sclerosis. The company emphasizes sustainability and workforce diversity in its operations.

Executive summary

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on branded prescription drugs primarily in hospital acute care, gastroenterology, and oncology. Its portfolio includes FDA-approved products such as Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, Vibativ, and Talicia. The company has ongoing clinical development programs for ifetroban targeting rare diseases. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. As of September 30, 2026, Cumberland reported $80.6 million in cash and equivalents, a current ratio of 3.05, and net income of $77.8 million for the nine months ended September 30, 2026, including gains from discontinued operations. Recent news highlights include FDA NDA submission for Dyscorban, Phase 2a trial results for ifetroban, and earnings call updates. The company faces generic competition pressures on some products and regulatory challenges related to manufacturing transfers.

Scenarios for CPIX

Bull case model:

Cumberland's portfolio includes several FDA-approved branded products with established market presence in hospital and specialty care settings. The company has demonstrated capability in product development, regulatory approvals, and commercialization, including expanded labeling and reimbursement milestones for Caldolor. Its clinical pipeline, notably ifetroban for Duchenne cardiomyopathy and systemic sclerosis, shows potential to address unmet medical needs. Strategic partnerships and international launches, such as Vibativ in China, support global reach. Strong liquidity and recent gains from asset disposals provide financial flexibility.

Bear case model:

The company faces risks from generic competition impacting branded products like Kristalose, which may affect market share and revenues. Manufacturing transitions, such as for Vaprisol, involve regulatory scrutiny and potential delays. Clinical development programs carry inherent risks of trial outcomes and regulatory approvals. The company's financial results include significant gains from discontinued operations, which may not be recurring. Market dynamics, including pricing pressures and reimbursement changes, could challenge profitability. Execution risks exist in integrating acquisitions and managing product portfolios effectively.

Moat:

Cumberland Pharmaceuticals' moat is supported by its portfolio of FDA-approved branded drugs with some products benefiting from patent protection and regulatory exclusivities, such as the EDTA-free formulation of Acetadote upheld by court rulings. Its focused sales divisions targeting concentrated prescriber bases in hospital acute care, gastroenterology, and oncology enable efficient market penetration. The company's ability to acquire and develop niche pharmaceutical products, combined with ongoing clinical programs for rare diseases, adds to its competitive positioning. However, generic competition and regulatory challenges in manufacturing represent ongoing pressures.

Risks overview
Risks summary
Key risks include generic competition affecting branded product sales, regulatory challenges in manufacturing transitions, uncertainties in clinical development programs, and reliance on non-recurring gains from discontinued operations.
Risks details:

• Generic Competition: Generic alternatives have entered the market for some branded products, notably Kristalose, increasing substitution rates and potentially impacting sales.
• Regulatory and Manufacturing Risks: Manufacturing transfers, such as for Vaprisol, require FDA approvals and resolution of regulatory issues, posing risks of supply disruptions.
• Clinical Development Uncertainty: Ongoing clinical trials for ifetroban and other candidates carry risks related to trial outcomes, regulatory feedback, and development timelines.
• Financial Dependence on Discontinued Operations Gains: Recent net income includes significant gains from disposal of discontinued operations, which may not recur and affect future profitability.

FINAL FORECAST FOR CPIX

Final take one line
Cumberland Pharmaceuticals exhibits very high visibility through detailed SEC disclosures and active clinical and commercial developments in specialty pharmaceuticals.
Final take 12 to 24 month view

Business trends: Continued focus on specialty branded pharmaceuticals with clinical development in rare diseases and expansion into international markets.
Execution milestones: Progress in FDA NDA submissions, clinical trial results for ifetroban, and commercial launches such as Vibativ in China.
Key risks: Generic competition, regulatory manufacturing challenges, clinical development uncertainties, and reliance on non-recurring financial gains.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

100
LLM visibility overview
LLM Visibility known facts
  • Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on acquisition, development, and commercialization of branded prescription pharmaceuticals primarily targeting hospital acute care, gastroenterology, and oncology markets in the U.S. [S1]
  • The company promotes its products through hospital, field, and oncology sales divisions in the U.S. and has international partnerships for regulatory and commercial capabilities outside the U.S. [S1]
  • Its FDA-approved marketed products include Acetadote (acetylcysteine injection for acetaminophen poisoning), Caldolor (ibuprofen injection for pain and fever), Kristalose (lactulose oral solution for constipation), Sancuso (granisetron transdermal patch for chemotherapy-induced nausea and vomiting), Vaprisol (conivaptan injection for hyponatremia), Vibativ (telavancin injection for serious bacterial infections), and Talicia (oral capsule for H. pylori infection). [S1]
  • The company has ongoing clinical development programs for ifetroban, including breakthrough results in cardiomyopathy associated with Duchenne muscular dystrophy (DMD), and Phase II trials in Systemic Sclerosis and Idiopathic Pulmonary Fibrosis. [S1]
  • Cumberland has core competencies in pharmaceutical acquisition, development, registration, and commercialization with experienced management teams across business development, regulatory, manufacturing, sales, marketing, and finance. [S1]
  • The company issued its inaugural Sustainability Report in 2019 and reported providing nearly 5 million patient doses in 2025 with no product recalls or clinical trial terminations due to poor standards. Workforce diversity includes 50% women and 30% minorities. [S1]
  • Acetadote has FDA orphan drug designation with expired exclusivity; the company developed a next-generation EDTA-free formulation with patent protection upheld by courts, preventing generic competition until August 2025. [S1]
  • Caldolor is the first FDA-approved injectable ibuprofen for pain and fever, with expanded labeling for pediatric use including infants aged 3 months and older, and a permanent CMS J-Code for reimbursement. [S1]
  • Kristalose is a prescription laxative in a dry powder crystalline formulation, marketed with dedicated sales and co-promotion partners, facing generic substitution pressures. [S1]
  • Sancuso is the first FDA-approved prescription patch for chemotherapy-induced nausea and vomiting, fully transitioned to Cumberland's commercial responsibility in the U.S. with an oncology sales division supporting it. [S1]
  • Vaprisol is an intravenous branded treatment for hyponatremia with manufacturing transferred to a new facility pending FDA approval. [S1]
  • Vibativ is an FDA-approved injectable antibiotic for serious Gram-positive infections including MRSA and MSSA, launched in China expanding global reach. [S1][N8]
  • Financial snapshot as of September 30, 2026: cash and equivalents $80.6M, current assets $104.6M, current liabilities $34.3M, current ratio 3.05, cash ratio 2.35. Net income for nine months ended September 30, 2026 was $77.8M including a gain on disposal of discontinued operations. Basic EPS was $5.19. [S2]
  • Recent developments include rolling FDA NDA submission for Dyscorban in Duchenne cardiomyopathy, top-line Phase 2a results for ifetroban in Systemic Sclerosis, and Q3 and Q2 earnings call highlights. [N1][N2][N3][N4]
  • Ifetroban shows potential to limit metastasis based on recent research. [N7]
  • The company reported a $100 million deal plan with Apotex to sell branded drugs. [N5][N6]
Sources
Sources - Context summary

Generated 2026-11-14

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-06 | 10-K
  • S2 | 2026-11-13 | 10-Q
Sources - News headlines
  • N1 | 2026-11-11 | www.nasdaq.com | Cumberland Pharmaceuticals Q3 Earnings Call Highlights | https://www.nasdaq.com/articles/cumberland-pharmaceuticals-q3-earnings-call-highlights
  • N2 | 2026-10-26 | www.nasdaq.com | Cumberland Pharmaceuticals Begins Rolling FDA NDA for Dyscorban in Duchenne Cardiomyopathy | https://www.nasdaq.com/articles/cumberland-pharmaceuticals-begins-rolling-fda-nda-dyscorban-duchenne-cardiomyopathy
  • N3 | 2026-10-23 | www.nasdaq.com | Cumberland Pharmaceuticals Inc. Announces Top-Line Results from Phase 2a ASSIST-SSc Trial | https://www.nasdaq.com/articles/cumberland-pharmaceuticals-inc-announces-top-line-results-phase-2a-assist-ssc-trial
  • N4 | 2026-08-04 | www.nasdaq.com | Cumberland Pharmaceuticals Q2 Earnings Call Highlights | https://www.nasdaq.com/articles/cumberland-pharmaceuticals-q2-earnings-call-highlights
  • N5 | 2026-08-04 | www.nasdaq.com | Top Biotech Gainers: UPC Cuts Loss, CPIX Gains Ahead Of Q2 Results, AUTL Builds Commercial Momentum | https://www.nasdaq.com/articles/top-biotech-gainers-upc-cuts-loss-cpix-gains-ahead-q2-results-autl-builds-commercial
  • N6 | 2026-07-31 | www.nasdaq.com | Possible Generic Drug Tariffs and 2 Microcaps | https://www.nasdaq.com/articles/possible-generic-drug-tariffs-and-2-microcaps
  • N7 | 2026-06-04 | www.nasdaq.com | Cumberland's Ifetroban Shows Potential to Limit Metastasis | https://www.nasdaq.com/articles/cumberlands-ifetroban-shows-potential-limit-metastasis
  • N8 | 2026-06-02 | www.nasdaq.com | Cumberland Expands Global Reach With Vibativ Launch in China | https://www.nasdaq.com/articles/cumberland-expands-global-reach-vibativ-launch-china
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine